Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00076024
Status:
COMPLETED
Last Update Posted:
2012-06-26
First Post:
2004-01-12
Brief Title:
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Randomized Placebo-Controlled Double-Blind Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to determine the time to progression of the combination of study drug AG-013736 and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None